Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Nov;66(5):629-39.
doi: 10.1111/j.1365-2125.2008.03276.x. Epub 2008 Jul 31.

Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study

Yan Feng  1 , Bruce G Pollock, Kim Coley, Stephen Marder, Del Miller, Margaret Kirshner, Manickam Aravagiri, Lon Schneider, Robert R Bies
Affiliations

Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study

Yan Feng et al. Br J Clin Pharmacol. 2008 Nov.

Abstract

Aims: To characterize pharmacokinetic (PK) variability of risperidone and 9-OH risperidone using sparse sampling and to evaluate the effect of covariates on PK parameters.

Methods: PK analysis used plasma samples collected from the Clinical Antipsychotic Trials of Intervention Effectiveness. A nonlinear mixed-effects model was developed using NONMEM to describe simultaneously the risperidone and 9-OH risperidone concentration-time profile. Covariate effects on risperidone and 9-OH risperidone PK parameters were assessed, including age, weight, sex, smoking status, race and concomitant medications.

Results: PK samples comprised 1236 risperidone and 1236 9-OH risperidone concentrations from 490 subjects that were available for analysis. Ages ranged from 18 to 93 years. Population PK submodels for both risperidone and 9-OH risperidone with first-order absorption were selected to describe the concentration-time profile of risperidone and 9-OH risperidone. A mixture model was incorporated with risperidone clearance (CL) separately estimated for three subpopulations [poor metabolizer (PM), extensive metabolizer (EM) and intermediate metabolizer (IM)]. Age significantly affected 9-OH risperidone clearance. Population parameter estimates for CL in PM, IM and EM were 12.9, 36 and 65.4 l h(-1) and parameter estimates for risperidone half-life in PM, IM and EM were 25, 8.5 and 4.7 h, respectively.

Conclusions: A one-compartment mixture model with first-order absorption adequately described the risperidone and 9-OH risperidone concentrations. Age was identified as a significant covariate on 9-OH risperidone clearance in this study.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Frequency histogram showing the age (a) and weight (b) distribution for all subjects in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)-SZ and CATIE-AD studies
Figure 2
Figure 2
Frequency histogram showing the sampling distribution for risperidone sampling measurements in Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)-SZ (a) and CATIE-AD (b) studies. The abscissa is broken into 1-h bins. The ordinate is the proportion of samples taken in each interval
Figure 3
Figure 3
Base population pharmacokinetic model structure for risperidone and 9-OH risperidone, KF is the fraction of risperidone to 9-OH risperidone
Figure 4
Figure 4
Diagnostic plots of final pharmacokinetic model. (a,e) Plot of observed concentrations vs. population predicted risperidone (a) and 9-OH risperidone (e) concentrations. Dots represent individual data points; solid line represents the unity line and dashed line represents the smooth line. (b,f) Plot of observed concentrations vs. individual population predicted risperidone (b) and 9-OH risperidone (f) concentrations. Dots represent individual data points; solid line represents the unity line and dashed line represents the smooth line. (c,g) Plot of weighted residual error (WRES) vs. population predicted risperidone (c) and 9-OH risperidone (g) concentrations. Dashed line represents the smooth line. (d,h) Plot of WRES vs. time after most recent dose for risperidone (d) and 9-OH risperidone (h). Dashed line represents the smooth line
Figure 5
Figure 5
9-OH risperidone clearance (CLM) vs. age. Line represents the smooth line
Figure 6
Figure 6
Histogram of risperidone clearance estimates (CL)
See this image and copyright information in PMC

References

    1. Spina E, Avenoso A, Facciola G, Salemi M, Scordo MG, Ancione M, Madia AG, Perucca E. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology (Berl) 2001;153:238–43. - PubMed
    1. Chouinard G, Arnott W. Clinical review of risperidone. Can J Psychiatry. 1993;38(Suppl 3):S89–95. - PubMed
    1. Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PA. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther. 1988;247:661–70. - PubMed
    1. Aichhorn W, Weiss U, Marksteiner J, Kemmler G, Walch T, Zernig G, Stelzig-Schoeler R, Stuppaeck C, Geretsegger C. Influence of age and gender on risperidone plasma concentrations. J Psychopharmacol. 2005;19:395–401. - PubMed
    1. Snoeck E, Van Peer A, Sack M, Horton M, Mannens G, Woestenborghs R, Meibach R, Heykants J. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology (Berl) 1995;122:223–9. - PubMed

Publication types

MeSH terms